1Y Target$48.47Near-term target
5Y Target$60.06Compound horizon
10Y Target$76.66Long-dated conviction
FCF$178mTTM · 12/25CFCF $178m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 12/25).
Rev+36.3%TTM YoYARevenue +36.3% — hypergrowth, top decile
D/E0.53totalB+D/E 0.53 — healthy leverage, well below danger zone · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E10.3xA-P/E 10.3 — cheap relative to market and most sectors
PEG0.28proxyAPEG 0.28 — exceptional; paying well under fair value for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Energy · market cap $1.9b. 7% off the 52-week high of $48.12. Revenue growing +36% — in hypergrowth territory. PEG 0.28 — paying under fair value for the growth rate.
Moat
Net margin 40% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Production-cost sensitivity — top-quartile cost producers generate cash through the cycle while marginal producers burn it; watch the cost-per-unit trend, not just headline revenue.
Horizon
1-3 yr $48.47 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $60.06 at ~6% CAGR — dividend + buyback compounding. 10 yr $76.66 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.